Overview

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea

Phase:

Phase 3

Details

Lead Sponsor:

Actavis Inc.

Collaborator:

Watson Laboratories, Inc.

Treatments:

Brimonidine Tartrate